Eric Sung1,2, Adityo Prakosa1,2, Konstantinos N Aronis2,3, Shijie Zhou1,2, Stefan L Zimmerman2,4, Harikrishna Tandri2,3, Saman Nazarian5, Ronald D Berger2,3, Jonathan Chrispin2,3, Natalia A Trayanova1,2. 1. Department of Biomedical Engineering (E.S., A.P., S.Z., N.A.T.), Johns Hopkins University, Baltimore, MD. 2. Alliance for Cardiovascular Diagnostic and Treatment Innovation (E.S., A.P., K.N.A., S.Z., S.L.Z., H.T., R.D.B., J.C., N.A.T.), Johns Hopkins University, Baltimore, MD. 3. Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine (K.N.A., H.T., R.D.B., J.C.), Johns Hopkins Hospital, Baltimore, MD. 4. Department of Radiological Sciences (S.L.Z.), Johns Hopkins Hospital, Baltimore, MD. 5. Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (S.N.).
Abstract
BACKGROUND: Infiltrating adipose tissue (inFAT) is a newly recognized proarrhythmic substrate for postinfarct ventricular tachycardias (VT) identifiable on contrast-enhanced computed tomography. This study presents novel digital-heart technology that incorporates inFAT from contrast-enhanced computed tomography to noninvasively predict VT ablation targets and assesses the capability of the technology by comparing its predictions with VT ablation procedure data from patients with ischemic cardiomyopathy. METHODS: Digital-heart models reflecting patient-specific inFAT distributions were reconstructed from contrast-enhanced computed tomography. The digital-heart identification of fat-based ablation targeting (DIFAT) technology evaluated the rapid-pacing-induced VTs in each personalized inFAT-based substrate. DIFAT targets that render the inFAT substrate noninducible to VT, including VTs that arise postablation, were determined. DIFAT predictions were compared with corresponding clinical ablations to assess the capabilities of the technology. RESULTS: DIFAT was developed and applied retrospectively to 29 ischemic cardiomyopathy patients with contrast-enhanced computed tomography. DIFAT ablation volumes were significantly less than the estimated clinical ablation volumes (1.87±0.35 versus 7.05±0.88 cm3, P<0.0005). DIFAT targets overlapped with clinical ablations in 79% of patients, mostly in the apex (72%) and inferior/inferolateral (74%). In 3 patients, DIFAT targets colocalized with redo ablations delivered years after the index procedure. CONCLUSIONS: DIFAT is a novel digital-heart technology for individualized VT ablation guidance designed to eliminate VT inducibility following initial ablation. DIFAT predictions colocalized well with clinical ablation locations but provided significantly smaller lesions. DIFAT also predicted VTs targeted in redo procedures years later. As DIFAT uses widely accessible computed tomography, its integration into clinical workflows may augment therapeutic precision and reduce redo procedures.
BACKGROUND: Infiltrating adipose tissue (inFAT) is a newly recognized proarrhythmic substrate for postinfarct ventricular tachycardias (VT) identifiable on contrast-enhanced computed tomography. This study presents novel digital-heart technology that incorporates inFAT from contrast-enhanced computed tomography to noninvasively predict VT ablation targets and assesses the capability of the technology by comparing its predictions with VT ablation procedure data from patients with ischemic cardiomyopathy. METHODS: Digital-heart models reflecting patient-specific inFAT distributions were reconstructed from contrast-enhanced computed tomography. The digital-heart identification of fat-based ablation targeting (DIFAT) technology evaluated the rapid-pacing-induced VTs in each personalized inFAT-based substrate. DIFAT targets that render the inFAT substrate noninducible to VT, including VTs that arise postablation, were determined. DIFAT predictions were compared with corresponding clinical ablations to assess the capabilities of the technology. RESULTS: DIFAT was developed and applied retrospectively to 29 ischemic cardiomyopathypatients with contrast-enhanced computed tomography. DIFAT ablation volumes were significantly less than the estimated clinical ablation volumes (1.87±0.35 versus 7.05±0.88 cm3, P<0.0005). DIFAT targets overlapped with clinical ablations in 79% of patients, mostly in the apex (72%) and inferior/inferolateral (74%). In 3 patients, DIFAT targets colocalized with redo ablations delivered years after the index procedure. CONCLUSIONS: DIFAT is a novel digital-heart technology for individualized VT ablation guidance designed to eliminate VT inducibility following initial ablation. DIFAT predictions colocalized well with clinical ablation locations but provided significantly smaller lesions. DIFAT also predicted VTs targeted in redo procedures years later. As DIFAT uses widely accessible computed tomography, its integration into clinical workflows may augment therapeutic precision and reduce redo procedures.
Authors: Takeshi Sasaki; Hugh Calkins; Christopher F Miller; Menekhem M Zviman; Vadim Zipunnikov; Tomio Arai; Motoji Sawabe; Masashiro Terashima; Joseph E Marine; Ronald D Berger; Saman Nazarian; Stefan L Zimmerman Journal: Heart Rhythm Date: 2015-03-23 Impact factor: 6.343
Authors: Antonio Esposito; Anna Palmisano; Sofia Antunes; Giuseppe Maccabelli; Caterina Colantoni; Paola Maria Vittoria Rancoita; Francesca Baratto; Clelia Di Serio; Giovanna Rizzo; Francesco De Cobelli; Paolo Della Bella; Alessandro Del Maschio Journal: JACC Cardiovasc Imaging Date: 2016-02-17
Authors: Michael Ghannam; Hubert Cochet; Pierre Jais; Maxime Sermesant; Smita Patel; Konstantinos C Siontis; Fred Morady; Frank Bogun Journal: J Cardiovasc Electrophysiol Date: 2018-03-05
Authors: Jim Pouliopoulos; William W B Chik; Ajita Kanthan; Gopal Sivagangabalan; Michael A Barry; Peter N A Fahmy; Christine Midekin; Juntang Lu; Eddy Kizana; Stuart P Thomas; Aravinda Thiagalingam; Pramesh Kovoor Journal: Circulation Date: 2013-09-13 Impact factor: 29.690
Authors: Patrick M Boyle; Tarek Zghaib; Sohail Zahid; Rheeda L Ali; Dongdong Deng; William H Franceschi; Joe B Hakim; Michael J Murphy; Adityo Prakosa; Stefan L Zimmerman; Hiroshi Ashikaga; Joseph E Marine; Aravindan Kolandaivelu; Saman Nazarian; David D Spragg; Hugh Calkins; Natalia A Trayanova Journal: Nat Biomed Eng Date: 2019-08-19 Impact factor: 25.671
Authors: Auriane C Ernault; Arie O Verkerk; Jason D Bayer; Kedar Aras; Pablo Montañés-Agudo; Rajiv A Mohan; Marieke Veldkamp; Mathilde R Rivaud; Rosan de Winter; Makiri Kawasaki; Shirley C M van Amersfoorth; Eva R Meulendijks; Antoine H G Driessen; Igor R Efimov; Joris R de Groot; Ruben Coronel Journal: Heart Rhythm Date: 2022-05-12 Impact factor: 6.779
Authors: Usama A Daimee; Eric Sung; Marc Engels; Marc K Halushka; Ronald D Berger; Natalia A Trayanova; Katherine C Wu; Jonathan Chrispin Journal: Heart Rhythm O2 Date: 2022-04-02